预测肿瘤对PD-1阻断疗法的反应。 - Suppr

Predicting Tumor Response to PD-1 Blockade.

作者信息

Ding Li, Chen Feng

机构信息

From the Department of Medicine (L.D., F.C.), McDonnell Genome Institute (L.D.), the Department of Genetics (L.D.), Siteman Cancer Center (L.D., F.C.), and the Department of Cell Biology and Physiology (F.C.) - all at Washington University School of Medicine, St. Louis.

出版信息

N Engl J Med. 2019 Aug 1;381(5):477-479. doi: 10.1056/NEJMcibr1906340.

DOI:10.1056/NEJMcibr1906340

PMID:31365807

Abstract

摘要

相似文献

Predicting Tumor Response to PD-1 Blockade.

N Engl J Med. 2019 Aug 1;381(5):477-479. doi: 10.1056/NEJMcibr1906340.

Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Oncologist. 2016 Oct;21(10):1200-1211. doi: 10.1634/theoncologist.2016-0046. Epub 2016 Jul 13.

Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.

Trends Cancer. 2017 Oct;3(10):675-677. doi: 10.1016/j.trecan.2017.08.002. Epub 2017 Sep 4.

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Science. 2018 Oct 12;362(6411). doi: 10.1126/science.aar3593.

Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.

Future Oncol. 2018 Aug;14(18):1869-1874. doi: 10.2217/fon-2017-0696. Epub 2018 Feb 23.

Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.

Science. 2019 May 3;364(6439):485-491. doi: 10.1126/science.aau0447.

Biomarkers for immune therapy in gastrointestinal cancers.

Clin Adv Hematol Oncol. 2019 Feb;17(2):109-119.

Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.

Acta Dermatovenerol Croat. 2018 Dec;26(4):341-343.

Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?

Bull Cancer. 2019 Feb;106(2):105-113. doi: 10.1016/j.bulcan.2018.08.007. Epub 2018 Oct 17.

Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.

Clin Colorectal Cancer. 2019 Dec;18(4):307-309. doi: 10.1016/j.clcc.2019.08.001. Epub 2019 Sep 4.

引用本文的文献

Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer.

Mater Today Bio. 2024 Nov 23;29:101358. doi: 10.1016/j.mtbio.2024.101358. eCollection 2024 Dec.

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.

Future Oncol. 2024;20(29):2149-2164. doi: 10.1080/14796694.2024.2376518. Epub 2024 Aug 5.

Decoding the Expressions, Immune Relevance, and Prognostic Values of Ferroptosis Gene TMEM189: A Pan-cancer Analysis.

Curr Cancer Drug Targets. 2025;25(5):520-537. doi: 10.2174/0115680096308701240605114342.

Mismatch repair gene correlates with the prognosis, immune status and immune checkpoint inhibitors response of endometrial cancer.

Front Immunol. 2024 Feb 8;15:1302797. doi: 10.3389/fimmu.2024.1302797. eCollection 2024.

Prediction of Prognosis, Immunotherapy and Chemotherapy with an Immune-Related Risk Score Model for Endometrial Cancer.

Cancers (Basel). 2023 Jul 19;15(14):3673. doi: 10.3390/cancers15143673.

A novel pyroptosis-associated lncRNA LINC01133 promotes pancreatic adenocarcinoma development via miR-30b-5p/SIRT1 axis.

Cell Oncol (Dordr). 2023 Oct;46(5):1381-1398. doi: 10.1007/s13402-023-00818-5. Epub 2023 May 4.

Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value.

Am J Transl Res. 2022 Sep 15;14(9):5952-5964. eCollection 2022.

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.

Front Oncol. 2021 Aug 19;11:729207. doi: 10.3389/fonc.2021.729207. eCollection 2021.

Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma.

Front Mol Biosci. 2021 Mar 3;8:625470. doi: 10.3389/fmolb.2021.625470. eCollection 2021.

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy.

Int J Nanomedicine. 2021 Mar 5;16:1889-1899. doi: 10.2147/IJN.S290796. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Predicting Tumor Response to PD-1 Blockade.

作者信息

Ding Li, Chen Feng

机构信息

出版信息

N Engl J Med. 2019 Aug 1;381(5):477-479. doi: 10.1056/NEJMcibr1906340.

DOI:10.1056/NEJMcibr1906340

PMID:31365807

Abstract

摘要

相似文献

Predicting Tumor Response to PD-1 Blockade.

N Engl J Med. 2019 Aug 1;381(5):477-479. doi: 10.1056/NEJMcibr1906340.

Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Oncologist. 2016 Oct;21(10):1200-1211. doi: 10.1634/theoncologist.2016-0046. Epub 2016 Jul 13.

Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.

Trends Cancer. 2017 Oct;3(10):675-677. doi: 10.1016/j.trecan.2017.08.002. Epub 2017 Sep 4.

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Science. 2018 Oct 12;362(6411). doi: 10.1126/science.aar3593.

Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.

Future Oncol. 2018 Aug;14(18):1869-1874. doi: 10.2217/fon-2017-0696. Epub 2018 Feb 23.

Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.

Science. 2019 May 3;364(6439):485-491. doi: 10.1126/science.aau0447.

Biomarkers for immune therapy in gastrointestinal cancers.

Clin Adv Hematol Oncol. 2019 Feb;17(2):109-119.

Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.

Acta Dermatovenerol Croat. 2018 Dec;26(4):341-343.

Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?

Bull Cancer. 2019 Feb;106(2):105-113. doi: 10.1016/j.bulcan.2018.08.007. Epub 2018 Oct 17.

Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.

Clin Colorectal Cancer. 2019 Dec;18(4):307-309. doi: 10.1016/j.clcc.2019.08.001. Epub 2019 Sep 4.

引用本文的文献

Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer.

Mater Today Bio. 2024 Nov 23;29:101358. doi: 10.1016/j.mtbio.2024.101358. eCollection 2024 Dec.

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.

Future Oncol. 2024;20(29):2149-2164. doi: 10.1080/14796694.2024.2376518. Epub 2024 Aug 5.

Decoding the Expressions, Immune Relevance, and Prognostic Values of Ferroptosis Gene TMEM189: A Pan-cancer Analysis.

Curr Cancer Drug Targets. 2025;25(5):520-537. doi: 10.2174/0115680096308701240605114342.

Mismatch repair gene correlates with the prognosis, immune status and immune checkpoint inhibitors response of endometrial cancer.

Front Immunol. 2024 Feb 8;15:1302797. doi: 10.3389/fimmu.2024.1302797. eCollection 2024.

Prediction of Prognosis, Immunotherapy and Chemotherapy with an Immune-Related Risk Score Model for Endometrial Cancer.

Cancers (Basel). 2023 Jul 19;15(14):3673. doi: 10.3390/cancers15143673.

A novel pyroptosis-associated lncRNA LINC01133 promotes pancreatic adenocarcinoma development via miR-30b-5p/SIRT1 axis.

Cell Oncol (Dordr). 2023 Oct;46(5):1381-1398. doi: 10.1007/s13402-023-00818-5. Epub 2023 May 4.

Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value.

Am J Transl Res. 2022 Sep 15;14(9):5952-5964. eCollection 2022.

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.

Front Oncol. 2021 Aug 19;11:729207. doi: 10.3389/fonc.2021.729207. eCollection 2021.

Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma.

Front Mol Biosci. 2021 Mar 3;8:625470. doi: 10.3389/fmolb.2021.625470. eCollection 2021.

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy.

Int J Nanomedicine. 2021 Mar 5;16:1889-1899. doi: 10.2147/IJN.S290796. eCollection 2021.

Predicting Tumor Response to PD-1 Blockade.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Predicting Tumor Response to PD-1 Blockade.

作者信息

机构信息

出版信息

相似文献

引用本文的文献